Medical Oncologist
Olaparib treatment duration
How Long Will You Stay on — Olaparib?
The honest answer depends on what olaparib is being used for. In some settings there is a fixed end date. In others, you continue until the cancer shows signs of progressing. Your oncologist knows which rule applies to you from the first prescription.
Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed August 2026
- Two different stopping rules — Fixed duration in some early-cancer settings; continue until progression in metastatic ones.
- Your situation is specific — The cancer type, stage, and reason olaparib was prescribed determine which rule applies to you.
- Side effects can also stop it — Unacceptable toxicity is a legitimate reason to stop, even without progression on scans.
- Stopping is not failure — Finishing a planned course or pausing for toxicity is a clinical decision, not a setback.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
How long you take olaparib depends on why it was prescribed. In some early-cancer settings, NCCN and ESMO guidance sets a defined treatment period from the start. In metastatic settings, you generally continue until your cancer progresses or side effects become unmanageable. Ask your oncologist which rule governs your prescription.
Does everyone take olaparib for the same length of time?
No. The duration depends on whether olaparib is being used to reduce the chance of your cancer returning after initial treatment, or to control cancer that has already spread.
In early-cancer settings — for example, after surgery and chemotherapy for certain BRCA-mutated cancers — NCCN and ESMO guidance sets a planned, finite treatment period. You and your oncologist know the expected end date from the beginning.
In metastatic settings — such as ovarian, breast, prostate, or pancreatic cancers that have spread — olaparib continues for as long as it is working and you can tolerate it. There is no fixed end date, and continuation is reviewed at every scan.
What would make your oncologist stop olaparib before the planned end?
Progression on imaging is the main clinical stopping point. If your scan shows the cancer has grown or spread despite treatment, olaparib is no longer doing its job and continuing it is not in your interest.
Significant side effects that do not settle with a dose reduction can also end treatment. Severe anaemia, persistent nausea, or kidney function changes may mean the risks outweigh the benefits for you specifically.
You can also stop because you choose to. That is a conversation to have with your oncologist — not a decision to make alone — but it is always on the table.
What do words like 'maintenance' and 'progression' actually mean?
- Maintenance therapy
- Olaparib taken after a good response to first treatment, to keep the cancer under control for as long as possible. In this setting, continuation depends on the cancer not progressing on scans.
- Adjuvant therapy
- Olaparib taken after surgery to reduce the risk of cancer returning. In adjuvant settings, a defined course length is set from the start.
- Disease progression
- The clinical term for cancer that has grown or spread despite treatment. Confirmed progression on imaging is the most common reason olaparib is stopped in metastatic settings.
- Dose reduction
- A planned decrease in the amount of olaparib taken each day, used to manage side effects while keeping treatment going. A dose reduction does not mean treatment is stopping.
- Treatment pause
- A temporary stop — usually a few weeks — to let the body recover from side effects. Olaparib is often restarted afterwards, sometimes at a lower dose.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
What should you tell your team while taking olaparib?
- Unusual tiredness or breathlessness — can signal anaemia that needs a blood check
- Nausea that stops you eating or drinking for more than a day
- New pain that feels different from before, especially bone pain or swelling
- Blood in urine or stool
- Any new supplement, herbal product, or over-the-counter medicine you have started
- Scan results from another hospital that your CION team has not yet seen
Did you know?
Olaparib was the first PARP inhibitor approved for BRCA-mutated cancers, and guidance on how long to use it continues to be refined as long-term follow-up data emerges.
NCCN and ESMO review their recommendations regularly — which means your oncologist's answer to 'how long' reflects the most current evidence, not a fixed rule that will never change.
Source: NCCN Clinical Practice Guidelines in Oncology; ESMO Clinical Practice Guidelines
Questions people ask about stopping olaparib
If I feel well, does that mean olaparib is working and I should keep taking it?
Feeling well is a good sign, but it does not confirm that olaparib is controlling the cancer. The only way to know is through imaging — CT, MRI, or PET-CT — and blood markers where they apply. Your team schedules these reviews at regular intervals. Do not adjust or stop olaparib based on how you feel without first discussing it with your oncologist.
What happens when olaparib stops working?
Your oncologist will discuss alternative treatments based on your cancer type, your previous treatment history, and what your body can manage at that point. Resistance to one PARP inhibitor does not automatically mean all options are exhausted. Other chemotherapy regimens, clinical trials, or targeted therapies may be available depending on your specific situation. Ask your team to lay out the next steps clearly at your review appointment.
Can I take a break from olaparib without telling my oncologist?
Please do not take a break without speaking to your team first. A gap that seems harmless can allow the cancer to progress in ways that are not immediately obvious, and some breaks affect how well the medicine works if you restart. If you are struggling with side effects or the daily demands of the medicine, your team may have practical solutions that keep treatment going safely. Your honesty directly affects the decisions your team can make for you.
Will I need to take olaparib for the rest of my life?
In most cases, no. Even in metastatic settings where there is no predetermined end date, most people eventually reach a stopping point — whether because the planned goal is achieved, progression occurs, or tolerability becomes an issue. In adjuvant settings, a defined course ends and most people do not restart unless their cancer returns and the situation is reassessed from the beginning with updated information.
Does stopping olaparib mean the cancer will come back straight away?
Not necessarily. In adjuvant settings, finishing a planned course means treatment has done what it was designed to do, and your cancer may remain in remission. In maintenance settings, some responses continue after stopping, though how long varies between individuals. Your oncologist will arrange monitoring scans after treatment ends to watch for any early signs of change. The fact that treatment has finished is not a signal to stop watching.
My oncologist wants to reduce my dose — does that mean it will not work as well?
Evidence reviewed by ASCO and ESMO suggests that a dose reduction to manage side effects does not necessarily reduce how well olaparib controls the cancer. Continuing at a lower, tolerable dose is generally considered better than stopping altogether. Your oncologist will choose the dose that balances effectiveness against a quality of life you can sustain over the long term. If you have concerns, ask your team to walk you through their reasoning.
Explore 75 more Kidney, Ovarian & Sarcoma Targeted Medicines topics
Drug Deep Dive: Olaparib (Lynparza)
- Adjuvant Olaparib After Early Breast Cancer Surgery
- Anaemia and Extreme Fatigue on Olaparib
- Blood Cancer Risk After Long-Term Olaparib: How Real Is It?
- Diet and Nutrition While on Olaparib
- Drug, Food and Supplement Interactions With Olaparib
- Fertility, Pregnancy and Contraception on Olaparib
- How Does Olaparib Work? The PARP Inhibitor Explained
- How Long Does Olaparib Take to Work?
- How Long Will You Stay on Olaparib?
- Maintenance Olaparib: Taking a Drug When There Is No Visible Cancer
- Nausea on Olaparib: Managing the Most Common Side Effect
- Olaparib (Lynparza, Olanib): The Complete Patient Guide
- Olaparib Myths: 'Only for BRCA', 'It's Chemo', 'It Causes Cancer'
- Olaparib Price in India: Brand, Generic and Monthly Cost
- Olaparib Side Effects: The Complete List and Timeline
- Olaparib Success Rate and Survival: An Honest Look at the Numbers
- Olaparib With Bevacizumab or Hormone Therapy: Combination Regimens
- Olaparib in Elderly Patients and Those With Other Illnesses
- Olaparib vs Niraparib vs Talazoparib: Comparing PARP Inhibitors
- Taking Olaparib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Olaparib
- When Olaparib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Olaparib? BRCA-Mutated Ovarian, Breast, Prostate and Pancreatic Cancer
- Will Insurance or a Government Scheme Pay for Olaparib?
- Work, Travel and Daily Life on Olaparib
Drug Deep Dive: Pazopanib (Votrient)
- Diarrhoea and Blood Pressure Rise on Pazopanib
- Diet and Nutrition While on Pazopanib
- Drug, Food and Supplement Interactions With Pazopanib
- Fertility, Pregnancy and Contraception on Pazopanib
- Hair Turning White and Skin Lightening on Pazopanib
- How Does Pazopanib Work? The Multi-Kinase Angiogenesis Inhibitor Explained
- How Long Does Pazopanib Take to Work?
- How Long Will You Stay on Pazopanib?
- Liver Toxicity on Pazopanib: Why LFTs Are Checked Every Two Weeks
- Pazopanib (Votrient, Pazonib): The Complete Patient Guide
- Pazopanib Combinations: Why It Is Usually Given Alone
- Pazopanib Myths: Hair Colour, Liver Damage and Stopping Early
- Pazopanib Price in India: Brand, Generic and Monthly Cost
- Pazopanib Side Effects: The Complete List and Timeline
- Pazopanib Success Rate and Survival: An Honest Look at the Numbers
- Pazopanib for Soft Tissue Sarcoma: What It Can and Cannot Do
- Pazopanib in Elderly Patients and Those With Other Illnesses
- Pazopanib in Kidney Cancer vs Sarcoma: Two Different Treatment Goals
- Pazopanib vs Sunitinib: Comparing Toxicity and Quality of Life
- Taking Pazopanib on an Empty Stomach: Why the Timing Rule Exists
- Tests and Monitoring While You Are on Pazopanib
- When Pazopanib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Pazopanib? Kidney Cancer and Soft Tissue Sarcoma
- Will Insurance or a Government Scheme Pay for Pazopanib?
- Work, Travel and Daily Life on Pazopanib
Drug Deep Dive: Sunitinib (Sutent)
- Diet and Nutrition While on Sunitinib
- Drug, Food and Supplement Interactions With Sunitinib
- Fertility, Pregnancy and Contraception on Sunitinib
- Hand-Foot Skin Reaction on Sunitinib: Prevention From Day One
- How Does Sunitinib Work? The Multi-Kinase Angiogenesis Inhibitor Explained
- How Long Does Sunitinib Take to Work?
- How Long Will You Stay on Sunitinib?
- Mouth Sores, Taste Loss and Yellow Skin Discolouration on Sunitinib
- Sunitinib (Sutent, Sunitix): The Complete Patient Guide
- Sunitinib After Kidney Surgery and for GIST: Two Different Settings
- Sunitinib Myths: Hair Colour Change, Dose Cuts and 'Weaker Treatment'
- Sunitinib Price in India: Brand, Generic and Monthly Cost
- Sunitinib Side Effects: The Complete List and Timeline
- Sunitinib Success Rate and Survival: An Honest Look at the Numbers
- Sunitinib and Immunotherapy: Where Combinations Fit in Kidney Cancer
- Sunitinib in Elderly Patients and Those With Other Illnesses
- Sunitinib vs Pazopanib vs Cabozantinib for Kidney Cancer
- Taking Sunitinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Sunitinib
- The 4-Weeks-On, 2-Weeks-Off Sunitinib Schedule and the 2/1 Alternative
- Thyroid Failure and Fatigue on Sunitinib: The Test to Repeat Every Cycle
- When Sunitinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Sunitinib? Kidney Cancer, GIST and Pancreatic Neuroendocrine Tumours
- Will Insurance or a Government Scheme Pay for Sunitinib?
- Work, Travel and Daily Life on Sunitinib
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
How long do you normally take olaparib?
It depends on why it was prescribed. In some early-cancer settings, NCCN and ESMO guidance recommends a defined course of treatment, and you will know the expected end date from the start. In metastatic settings, you continue for as long as olaparib is controlling the cancer and you can tolerate it. Ask your oncologist at your first appointment which of these applies to you and what the review points will be.
Can olaparib be stopped and restarted?
A temporary pause for side effects is common, and many people restart olaparib afterwards — sometimes at a reduced dose. Stopping because of confirmed progression on imaging is different: in that situation, restarting the same treatment is unlikely to help and your oncologist will discuss alternatives. If you are considering stopping for personal reasons, talk to your team first so you understand the full implications.
How will my oncologist know when to stop olaparib?
In fixed-duration settings, the stopping point was planned from the beginning. In maintenance or metastatic settings, continuation is reviewed at each imaging appointment. If scans show the cancer is growing despite treatment, your team will have a direct conversation about stopping and what comes next. You should not have to guess — ask your oncologist what the specific review points are for your situation.
What if I want to stop olaparib before my oncologist recommends it?
That is your right. Tell your team what is driving the decision — whether it is side effects, practical difficulties, or something else — because many of those things can be addressed before stopping becomes necessary. If you have thought it through and still want to stop, your team should help you make that decision with full information, including how frequently to monitor afterwards. Do not stop suddenly without having that conversation first.
Is olaparib still working if my side effects have improved?
Yes. Improved side effects usually mean your body has adjusted to the medicine, not that it has stopped working. Side effects from olaparib tend to be most noticeable in the first few weeks and often settle over time or after a dose adjustment. Whether olaparib is controlling the cancer is assessed through scans and relevant blood markers, not through how you feel from day to day.
Will I need olaparib again if my cancer comes back after finishing a course?
Possibly, but it depends on how long you have been off it, what alternatives are available, and whether your cancer is still likely to respond. NCCN and ESMO guidance on re-treatment after PARP inhibitors continues to evolve as new evidence emerges. If your cancer returns after a planned course, your oncologist will reassess from the beginning — including your treatment history and current biomarker status — before recommending a next step.